Contrasting Affymax (AFFY) and Trillium Therapeutics (TRIL)
Affymax (OTCMKTS: AFFY) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Earnings and Valuation
This table compares Affymax and Trillium Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Trillium Therapeutics||N/A||N/A||-$27.80 million||($3.73)||-1.35|
Trillium Therapeutics has higher revenue, but lower earnings than Affymax.
This is a summary of current ratings for Affymax and Trillium Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trillium Therapeutics has a consensus price target of $16.50, indicating a potential upside of 226.73%. Given Trillium Therapeutics’ higher probable upside, analysts plainly believe Trillium Therapeutics is more favorable than Affymax.
Institutional & Insider Ownership
48.0% of Trillium Therapeutics shares are owned by institutional investors. 1.6% of Affymax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Affymax has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
This table compares Affymax and Trillium Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Affymax beats Trillium Therapeutics on 5 of the 9 factors compared between the two stocks.
Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
About Trillium Therapeutics
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Affymax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.